= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Rappold

MSACL 2018 EU Abstract

Topic: Practical Training

Podium Presentation in the Ether on Thursday at 14:50 (Chair: Brian Rappold)

2/3 Getting Lower Limits of Quantification in LC-MS/MS assays : Phases and Stages

Brian Rappold (Presenter)

Presenter Bio(s): Brian Rappold is the Director of Mass Spectrometry for LabCorp. He's participated in MSACL EU since its inception, leading workshops and teaching short courses related to method development and validation strategies.

Authors: Brian Rappold
Laboratory Corporation of America


The second of 3 lectures on improving instrument response will focus on the approaches and experimentation used in LC-MS/MS assays. Understanding that increased response can only be generated in two phases of the LC-MS/MS process (material loaded into the system and ionization cross-section), a series of examples on scientifically defining “optimization” will be walked through.

Financial Disclosure

Board MemberyesMetabolomic Diagnostics
Stockyes LabCorp
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: